The NHS Test and Trace Programme is launched, Gilead’s remdesivir becomes available under the Early Access to Medicines Scheme and BIA members continue to ramp up UK vaccine manufacturing capacity.
Plus, the BIA innovates this week with the popular Women in Biotech series moving to a virtual setting!
The use of animals in research continues to rank highly in the public consciousness, with a 2018 Ipsos MORI poll showing that three-fifths of people are interested in the methods used by scientists to replace, reduce and refine the use of animals in research (the 3Rs). The UK’s National Centre for the Replacement, Refinement and Reduction of Animals in Research (the NC3Rs) is committed to furthering this goal. Its programme includes a long-standing collaboration with the pharmaceutical industry that has led to changes in company practice and regulatory guidelines.
AstraZeneca receives $1.2bn to scale-up and deliver Oxford’s COVID-19 vaccine, antibody testing gains momentum as a deal is struck between Roche and the NHS and details start to emerge on the future of the UK’s relationship with the EU.
Pharmaceutical, healthcare and biotech companies are at the forefront of the COVID-19 response, from therapeutic drug trials and vaccine development to the production of personal protective equipment (PPE) and ventilators.
UK vaccine taskforce builds vaccine manufacturing capability in the UK, more details on government support for life science businesses and the approval of a coronavirus antibody test, as the UK begins exit from lockdown
The Prime Minister’s announcements; last night and this afternoon move the UK into the next phase of the pandemic response. Over the past week we have heard more detail on the test, track and trace initiative which will help in lifting restrictions, we have seen continued global collaboration to tackle the virus and have received details from the NIHR on restarting clinical trials.
Given recent events, huge swathes of us have suddenly had to start working remotely in order to help slow the spread of COVID-19 and ease the strain on healthcare systems globally. Scientific researchers play a key role in the fight against the virus as well as other important global challenges, but is it even possible to continue research remotely?